Associations of Human Papillomavirus (HPV) genotypes with high-grade cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South Africa. by Kelly, Helen A et al.
Kelly, HA; Ngou, J; Chikandiwa, A; Sawadogo, B; Gilham, C; Omar,
T; Lompo, O; Doutre, S; Meda, N; Weiss, HA; Delany-Moretlwe, S;
Segondy, M; Mayaud, P; HARP Study Group (2017) Associations
of Human Papillomavirus (HPV) genotypes with high-grade cervical
neoplasia (CIN2+) in a cohort of women living with HIV in Burkina
Faso and South Africa. PLoS One, 12 (3). e0174117. ISSN 1932-6203
DOI: 10.1371/journal.pone.0174117
Downloaded from: http://researchonline.lshtm.ac.uk/3682757/
DOI: 10.1371/journal.pone.0174117
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE
Associations of Human Papillomavirus (HPV)
genotypes with high-grade cervical neoplasia
(CIN2+) in a cohort of women living with HIV in
Burkina Faso and South Africa
Helen A. Kelly1☯*, Jean Ngou2☯, Admire Chikandiwa3☯, Bernard Sawadogo4☯,
Clare Gilham1☯, Tanvier Omar5☯, Olga Lompo4☯, Sylviane Doutre2☯, Nicolas Meda4☯,
Helen A. Weiss6,7☯, Sinead Delany-Moretlwe5☯, Michel Segondy2☯, Philippe Mayaud1,3☯,
for the HARP Study Group¶
1 Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United
Kingdom, 2 INSERM U1058 and University Hospital (CHRU), Montpellier, France, 3 Wits Reproductive
Health and HIV Institute, University of the Witwatersrand, Johannesburg, South Africa, 4 Centre de
Recherches Internationales en Sante´, University of Ouagadougou, Ouagadougou, Burkina Faso, 5 National
Health Laboratory Services, Johannesburg, South Africa, 6 Department of Infectious Disease Epidemiology,
London School of Hygiene and Tropical Medicine, London, United Kingdom, 7 MRC Tropical Epidemiology
Group, London School of Hygiene and Tropical Medicine, London, United Kingdom
☯ These authors contributed equally to this work.
¶ The complete membership of the author group can be found in the Acknowledgments section.
* helen.kelly@lshtm.ac.uk
Abstract
Objective
To describe associations of high-risk human papillomavirus (HR-HPV) with high-grade cer-
vical intraepithelial neoplasia (CIN2+) in women living with HIV (WLHIV) in Burkina Faso
(BF) and South Africa (SA).
Methods
Prospective cohort of WLHIV attending HIV outpatient clinics and treatment centres.
Recruitment was stratified by ART status. Cervical HPV genotyping using INNO-LiPA and
histological assessment of 4-quadrant cervical biopsies at enrolment and 16 months later.
Results
Among women with CIN2+ at baseline, the prevalence of any HR-HPV genotypes included
in the bi/quadrivalent (HPV16/18) or nonavalent (HPV16/18/31/35/45/52/58) HPV vaccines
ranged from 37% to 90%. HPV58 was most strongly associated with CIN2+ (aOR = 5.40,
95%CI: 2.77–10.53). At 16-months follow-up, persistence of any HR-HPV was strongly
associated with incident CIN2+ (aOR = 7.90, 95%CI: 3.11–20.07), as was persistence of
HPV16/18 (aOR = 5.25, 95%CI: 2.14–12.91) and the additional HR types in the nonavalent
vaccine (aOR = 3.23, 95%CI: 1.23–8.54).
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Conclusion
HR-HPV persistence is very common among African WLHIV and is linked to incident CIN2+.
HPV vaccines could prevent between 37–90% of CIN2+ among African WLHIV.
Introduction
Women living with HIV (WLHIV) have a higher prevalence of genital high-risk human papil-
lomavirus (HR-HPV) infection than the general population [1], are more likely to be infected
with multiple HR types [2, 3] and have greater persistence of infection [4] and risk of cervical
intraepithelial neoplasia (CIN) progression [5]. WLHIV have been shown to be more com-
monly infected with types other than HPV16 or 18 [6] and their high-grade cytological lesions
are frequently attributed to types other than HPV16/18 [3].
As WLHIV are living longer due to increased availability of antiretroviral therapy (ART),
many retain a high risk of infection with HPV and high risk of progressing to cervical and
other genital cancers. Primary prevention of HPV infection through vaccination could reduce
the burden of infection and disease and on screening and treatment services. Current bivalent
and quadrivalent HPV vaccines target two HR types (HPV16 and 18) responsible for about
70% of cervical cancers [7], whereas the nonavalent vaccine which protects against a wider
range of HR-HPV types (HPV16/18/31/33/45/52/58), is estimated to prevent up to 90% of cer-
vical cancers in women from the general population [7, 8]. These potential benefits have sel-
dom been estimated among WLHIV, particularly in sub-Saharan Africa. An improved
understanding of HPV type distribution associated with histological lesions in this population
is needed to guide HPV vaccine programme decisions.
We conducted a large prospective study of cervical cancer screening in a cohort of women
living with HIV-1 in Burkina Faso and South Africa (HARP—HPV in Africa Research Partner-
ship). In this paper, we describe (i) the prevalence, persistence, incidence and genotype distri-
bution of HPV, and (ii) their association with prevalent and incident CIN grade 2 and higher
(CIN2+).
Materials and methods
Study population
Participants were recruited from the HIV outpatient clinic of the University Teaching Hospital
of Ouagadougou, Burkina Faso (BF), and HIV treatment centres from inner city Johannesburg
South Africa (SA), from December 2011 to October 2012. Inclusion criteria were being HIV-1
seropositive, aged 25–50 years and resident in the city. Exclusion criteria were history of prior
treatment for cervical cancer, previous hysterectomy, and being pregnant or less than 8 weeks
postpartum. Enrolment was stratified in a 2:1 ratio of ART-users:ART-naïve. Written
informed consent was obtained at the screening visit when eligibility for the study was
assessed. Participants were followed-up every 6 months for CD4+ T-lymphocytes cell count
and up to Month 18 (endline) when procedures similar to baseline were repeated.
Specimen collection
A venous blood sample was collected to confirm HIV-1 serostatus if necessary, and to obtain
CD4+ cell counts. Cervical samples were collected by a nurse-midwife including a Digene cervi-
cal sampler at enrolment (baseline) and careHPV cervical sampler at endline (both Qiagen,
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Gaithesburg, MD) for HPV-DNA testing and genotyping. All women were screened for abnor-
mal cervical lesions using cervical smear for cytology by Papanicolaou staining and visual
inspection using acetic acid and Lugol’s iodine (VIA/VILI), and referred for colposcopy per-
formed by trained colposcopists. Systematic 4-quadrant cervical biopsy, including directed
biopsy of any suspicious lesions, was performed for participants who had abnormalities detected
on cytology, VIA/VILI or colposcopy, or who were HR-HPV DNA positive. The same genital
sampling and examination procedures were repeated at a scheduled follow-up visit at Month 18.
Laboratory testing
HIV infection was diagnosed according to national guidelines for each country [9, 10]. Mea-
surement of CD4+ cell count was performed using FACScount (Becton-Dickinson, NJ) in
both countries. HPV-DNA genotyping of all samples was performed at the virology laboratory
of the Gui de Chauliac Teaching Hospital, University of Montpellier, France, using the
INNO-LiPA HPV genotyping Extra1 assay (Fujirebio, Courtaboeuf, France) with external
quality assurance [11]. HR-HPV types were defined using the current International Agency
for Research on Cancer (IARC) classification [12] to include ‘carcinogenic to humans’
(HPV16/18/31/33/35/39/45/51/52/56/58/59) and ‘probable carcinogenic’ (HPV68). The ‘possi-
ble carcinogenic’ types (HPV26/53/66/69/70/73/82) and other known low-risk types (HPV6/
11/40/43/44/54/71/74) were considered as low-risk (LR-HPV).
Cervical biopsies were processed at the local pathology laboratories in Ouagaoudou and
Johannesburg and read using the 3-tier CIN classification system [13]. Histology was classified
as “negative” (CIN1) or “positive” (CIN2+) based on the highest reading across all findings
from the 4-quadrant biopsies and endocervical curettage, if indicated. All histological slides
from women with a local diagnosis of CIN2+ and approximately 10% of slides from women
with normal or CIN1 histological findings were reviewed by the HARP Endpoint Committee
of five pathologists for final classification, after baselineand endline rounds.
Statistical analysis
HR-HPV genotype-specific persistence was defined as being positive for the same HR-HPV
type at baseline and endline visits. Any type clearance was defined as being positive for a spe-
cific HR type at baseline and negative for that type at endline visit. Cumulative incidence of
any HR-HPV was defined as the proportion of women who were negative for a specific type at
baseline and positive for that type at endline visit.
For associations of prevalent and incident CIN2+ with individual HR-HPV types, logistic
regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CI). Multi-
variable analyses adjusted for site and the socio-demographic and behavioural factors which
were independently associated in univariate analyses (p<0.10) with CIN2+ for each country,
as described in [14], were conducted. Data were analysed using Stata version 14 (Stata Statisti-
cal Software, College Station. TX: Stata Corporation).
This study received ethical approval from the Ministry of Health in Burkina Faso (no. 2012-
12-089), the University of the Witwatersrand in South Africa (no. 110707), and the London
School of Hygiene and Tropical Medicine in the UK (no. 7400).
Results
Study population
A full description of study participants has been published elsewhere [14]. Of 1479 women
screened, 1238 were enrolled (BF: 615; SA: 623). The median age of participants was 36
HPV types and CIN2+ in HIV-1 infection
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(interquartile range [IQR], 31–42) years in BF and 34 (IQR, 30–40) years in SA. About half
(49.7%) of SA participants had ever had a Pap smear, and a fifth (20.8%) of BF participants had
ever had a VIA/VILI examination, the primary cervical cancer screening modality in each
country respectively. At enrolment, 422 (68.6%) participants were on ART in BF and 406
(65.2%) in SA. In BF, the median CD4+ count was 417 (IQR, 315–606) cells/mm3 among
ART-naive participants and 446 (IQR, 309–600) cells/mm3 among ART users. In SA, the
median CD4+ count was 448 (IQR, 353–614) cells/mm3 among ART-naive and 420 (IQR,
279–567) cells/mm3 among ART users.
Prevalence of HPV and association with CIN2+ at enrolment
Of the 1238 participants enrolled, 1215 (98.1%) had valid HPV genotyping results (BF: 96.6%;
SA: 99.7%) and 998 (82.1%) were positive for any HPV (BF: 75.3%; SA: 88.7%). The propor-
tion of multiple HR-HPV genotypes was lower in BF (BF: 41.9% vs. SA: 55.2%; p<0.001;
Table 1). HPV52 was the most prevalent type in both countries (BF: 20.4%; SA: 24.2%).
HPV16/18 were detected in 15.0% of participants in BF vs. 29.0% in SA (p<0.001). Among
those without HPV16/18 co-infection, the proportion infected by any of the additional HR
types included in the nonavalent (9v) vaccine (HPV31/33/45/52/58) was 30.1% in BF and
36.7% in SA (p<0.001). The prevalence of any of the non-vaccine HR types (HPV35/39/51/
56/59/68) was 35.5% in BF and 49.1% in SA (p<0.001) irrespective of co-infection with any of
the vaccine types, and was 14.0% in BF and 13.4% in SA among those not co-infected by any
vaccine types.
Among women with both histology and HPV results (BF: 546; SA: 573), the prevalence of
HR-HPV was higher among those with higher CIN grades in both settings (BF: 48.4% in CIN
normal, 71.8% in CIN1, 100% in CIN2 and 100% in CIN3+, p<0.001; SA: 72.4% in CIN nor-
mal, 81.4% in CIN1, 89.5% in CIN2 and 92.5% in CIN3+, p<0.001;) (Fig 1(A) and 1(B)). The
prevalence of any HR-HPV genotypes included in the bi/quadrivalent and nonavalent HPV
vaccines was 45.2% and 90.3% among women with CIN2+ in BF, respectively, and 37.2% and
79.8% in SA, respectively. In the absence of any vaccine types, the prevalence of any non-vac-
cine types was 9.7% (3/31) in BF and 10.9% (14/129) in SA.
In both countries, HPV58 was the genotype most strongly associated with CIN2 compared
toCIN1 cases (adjusted Odds Ratio [aOR] = 5.40, 95%CI: 2.77–10.53), while types most
strongly associated with CIN3+ were HPV16 in BF (aOR = 34.56, 95%CI: 5.70–209.49) and
HPV58 in SA (aOR = 3.65, 95%CI: 1.42–9.37) (Fig 2(A) and 2(B) and S1 Table). The preva-
lence of HPV58 was 22.1% and 21.1% among women with CIN2 in BF and SA respectively,
and 23.1% and 15.1% among women with CIN3+.
The prevalence of CIN2+ was significantly higher among those positive for HPV16/18 com-
pared to those who were negative for both types in BF (17.7% vs. 3.6%; aOR = 7.90, 95%CI:
3.23–19.33) and in SA (29.1% vs. 19.9%, aOR = 1.49, 95%CI: 0.95–2.34), although the latter
was not statistically significant (S1 Table). Among 875 women without co-infection of either
HPV16 or 18, the prevalence of CIN2+ was higher among women positive for any of the addi-
tional HR-HPV types targeted by the nonavalent vaccine (31/33/45/52/58) compared to
women negative for all of these types in both countries (BF: 8.8% vs. 1.0%; SA: 25.2% vs.
13.7%; aOR = 2.78, 95%CI: 1.67–4.64 for both countries combined). The prevalence of CIN2+
was similar among women who were positive or negative for any of the non-vaccine HR-HPV
types. However, among 498 women without infection with vaccine types (BF: 308, SA: 190),
the prevalence of CIN2+ was higher among women positive for any of the non-vaccine types
compared to women who were HR-HPV negative (11.1% vs. 3.4%; aOR = 3.35, 95%CI: 1.36–
8.26).
HPV types and CIN2+ in HIV-1 infection
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Incidence and persistence of HR-HPV
Of the 963 women without CIN2+ at enrolment who returned at follow-up M18 visit (median
of actual follow-up 16 months [IQR, 15.6–16.8]), genotyping data at both visits was available
for 922 (95.7%) women. The proportion of women with an incident HR-HPV infection was
similar in both sites (BF: 47.9% [228/476] vs. SA: 49.3% [220/446]; p = 0.67). Type-specific
incident infection was highest for HPV52 in both countries (BF: 12.7%; SA: 16.6%). Incident
infection of HPV16/18 was observed in 14.6% of women in BF and 14.7% in SA. In the absence
of HPV16/18 co-infection, incident infection of any of the additional HR-HPV types of the
nonavalent vaccine was observed in 19.7% of women in BF and 23.9% in SA; incident infection
Table 1. HR-HPV infection at baseline and endline follow-up among Women Living with HIV (WLHIV) in Burkina Faso (BF) and South Africa (SA).
HR-HPV Prevalence HR-HPV Incidence HR-HPV Persistence
BF
N = 594
n (%)
SA
N = 621
n (%)
BF SA BF SA
At riska
N
Incidence
n (%)
At riska
N
Incidence
n (%)
Positive at M0
N
Persistence
n (%)
Positive at M0
N
Persistence
n (%)
Any HR typeb 351 (59.1) 491 (79.1) 476 228 (47.9) 446 220 (49.3) 270 139 (51.5) 340 152 (44.7)
Any alpha-9 264 (44.4) 392 (63.1) 476 152 (31.9) 446 154 (34.5) 198 98 (49.5) 260 99 (38.1)
HPV16 51 (8.6) 119 (19.2) 445 43 (9.7) 377 49 (13.0) 31 17 (54.8) 69 23 (33.3)
HPV31 47 (7.9) 65 (10.5) 445 44 (9.9) 404 22 (5.5) 31 19 (61.3) 42 6 (14.3)
HPV33 19 (3.2) 51 (8.2) 464 8 (1.7) 419 17 (4.1) 12 3 (25.0) 27 4 (14.8)
HPV35 62 (10.4) 103 (16.6) 429 24 (5.6) 385 34 (8.8) 47 18 (38.3) 61 26 (42.6)
HPV52 121 (20.4) 150 (24.2) 378 48 (12.7) 337 56 (16.6) 98 37 (37.8) 109 39 (35.8)
HPV58 27 (4.6) 55 (8.9) 458 15 (3.3) 417 14 (3.4) 18 13 (72.2) 29 11 (37.9)
Any alpha-7 117 (19.7) 198 (31.9) 476 117 (24.6) 446 122 (27.4) 89 37 (41.6) 145 46 (31.7)
HPV18 42 (7.1) 90 (14.5) 445 29 (6.5) 378 18 (4.8) 31 17 (54.8) 68 24 (35.3)
HPV39 43 (7.2) 50 (8.1) 442 24 (5.4) 408 25 (6.1) 34 7 (20.6) 38 8 (21.1)
HPV45 26 (4.4) 48 (7.7) 457 12 (2.6) 415 22 (5.3) 19 11 (57.9) 31 11 (35.5)
HPV59 6 (1.0) 12 (1.9) 473 4 (0.9) 436 5 (1.2) 3 0 (0.0) 10 2 (20.0)
HPV68 23 (3.9) 35 (5.6) 457 24 (5.3) 424 28 (6.6) 19 3 (15.8) 22 4 (18.2)
Alpha-5 and -6
HPV51 70 (11.8) 97 (15.6) 423 30 (7.1) 378 22 (5.8) 53 15 (28.3) 68 18 (26.5)
HPV56 25 (4.2) 60 (9.7) 456 45 (9.9) 408 16 (3.9) 20 11 (55.0) 38 9 (23.7)
Combinations
HPV16/18 89 (15.0) 180 (29.0) 473 69 (14.6) 422 62 (14.7) 59 33 (55.9) 113 45 (39.8)
Other 9vHPVc 179 (30.1) 228 (36.7) 473 93 (19.7) 422 101 (23.9) 155 70 (42.5) 198 61 (30.8)
Any 9vHPV HRd 268 (45.1) 408 (65.7) 476 162 (34.0) 446 163 (36.6) 200 103 (51.5) 275 106 (38.6)
Non-Vaccinee 83 (14.0) 83 (13.4) 473 66 (14.0) 422 57 (13.5) 112 36 (32.1) 141 46 (32.6)
Multiple HR 147/351 (41.9) 271/491 (55.2) 228 81 (35.5) 220 79 (35.9) 270 27/139 (19.4) 340 27/152 (17.8)
Low risk types
HPV6 34 (5.7) 33 (5.3) 450 22 (4.9) 422 13 (3.1) 26 6 (23.1) 24 2 (8.3)
HPV11 9 (1.5) 33 (5.3) 470 3 (0.6) 420 15 (3.6) 6 1 (16.7) 26 4 (15.4)
anegative for that HPV type at enrolment (3 participants in BF with positive 16 AND 18 at enrolment, and 24 in SA; no participant was infected by ALL
nonavalent HR types or ALL non vaccine types;
bAny HR-HPV type prevalence defined as positive for at least one HR type at baseline; any HR incidence defined as incident infection from at least one HR
type among those at risk for any HR infection (no participant was infected by all HR types at baseline); persistence defined as persistence of at least one HR
type among those positive for any HR type at baseline;
cOther 9vHPV = Positive for any of HPV31/33/45/52/ 58 in absence of HPV16/18;
d9vHPV HR = Positive for any of HPV16/18/31/33/45/52/58;
eNon Vaccine = Positive for any of HPV35/39/51/56/59/68 in absence of any vaccine type.
https://doi.org/10.1371/journal.pone.0174117.t001
HPV types and CIN2+ in HIV-1 infection
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of non-vaccine HR-HPV types in the absence of vaccine type co-infection was observed in
14.0% in BF and 13.5% in SA (Table 1).
Persistence was highest for HPV58 (72.2%) in BF and HPV35 (42.6%) in SA. Forty-nine
women (18.2%) in BF and 80 (23.5%) in SA had at least one persistent and one cleared infec-
tion during the 16 months follow-up period (Table 1).
Fig 1. (A) HR-HPV prevalence by CIN grade among 546 women living with HIVin Burkina Faso. (B) HR-HPV
prevalence by CIN grade among 573 women living with HIV in South Africa.
https://doi.org/10.1371/journal.pone.0174117.g001
HPV types and CIN2+ in HIV-1 infection
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Association of incident CIN2+ with HR-HPV persistence
Among 922 women with genotyping data at both visits, concomitant histology results were
available for 780 (84.6%) women (BF: 405; SA: 375). Cumulative incidence of CIN2+ was
higher among those with HR-HPV persistence compared to those who cleared or who were
HR-HPV negative at baseline in both settings (BF: 3.5% vs. 0.3%; SA: 13.4% vs. 2.0%; both
countries combined aOR = 7.90, 95%CI: 3.11–20.07, Table 2).
CIN2+ incidence was found to be significantly associated with the persistence of any mem-
bers of the alpha-9 HPV (HPV16-related) and any alpha-7 HPV (HPV-18 related) genotypes
in both countries (Table 2). In particular, CIN2+ incidence was higher among women with
persistent HPV16/18 compared to those who cleared either or who were negative for both at
Fig 2. (A) Association of HR-HPV prevalence with prevalent CIN2 and CIN3+ among 546 women living with HIV in
Burkina Faso. (B) Association of HR-HPV prevalence with prevalent CIN2 and CIN3+ among 573 women living with
HIV in South Africa.
https://doi.org/10.1371/journal.pone.0174117.g002
HPV types and CIN2+ in HIV-1 infection
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baseline (BF: 7.7% vs. 0.8%; SA: 18.2% vs. 4.7%; both sites combined: aOR = 5.25, 95%CI:
2.14–12.91).
Among 721 women without persistent HPV16 or 18, CIN2+ incidence was higher among
those with persistence of any of the additional 5 HR-HPV included in the nonavalent (both
sites combined: 6.1% vs. 2.0% aOR = 3.23, 95%CI: 1.23–8.54). In the absence of co-persistence
by any of the vaccine types (606 women), CIN2+ incidence was higher among women with
persistent non-vaccine types compared to those who cleared or who were HR-HPV negative at
baseline in both settings (8.1% vs. 1.1%; aOR = 7.87, 95%CI: 2.40–25.81).
Association of HIV-related factors with HR-HPV prevalence at baseline
The prevalence of HR-HPV types was similar among ART users and ART-naive participants
at baseline in BF, whilst in SA, the prevalence of HPV16/18 was higher among ART-naïve par-
ticipants (S2 and S3 Tables). Among ART users in BF, the prevalence of any nonavalent
HR-HPV in the absence of HPV16/18 was higher among women with low CD4+ count (<200
cells/mm3) compared to those with high CD4+ count (>500 cells/mm3) and this association
was significant among ART users only, however no association was observed for HPV16/18 or
the non-vaccine types. In SA, only the prevalence of non-vaccine HR-HPV was higher among
ART-taking women with low CD4+ count (S3 Table).
Discussion
Women living with HIV (WLHIV) in Burkina Faso and South Africa have a high prevalence,
incidence and persistence of HR-HPV and correspondingly a high prevalence and incidence
of cervical neoplasia. The high rates of HR-HPV found in both countries are similar to other
studies in Sub Saharan Africa [1, 2, 15, 16]. The increased risk in the prevalence of HR-HPV
and CIN2+ among women in South Africa compared to Burkina Faso may be explained by the
less well controlled HIV disease (in terms of lower rates of ART adherence and HIV viral sup-
pression) found among women in South Africa, as we reported elsewhere [14], as well as by
other cofactors for HR-HPV and CIN2+, such as greater frequency of contraceptive use and
smoking and higher prevalence of mucosal STIsobserved in this and other cohort of WLHIV
[17–25].
While HR-HPV prevalence was higher in South Africa at baseline, HR-HPV persistence
was higher among women in Burkina Faso. This may be due to the fact that estimates of
HR-HPV persistence were restricted to women without evidence of CIN2+ at baseline, who
underwent treatment. As there was a higher prevalence of CIN2+ at baseline in South Africa,
their exclusion from the follow-up analysis potentially reduced the overall proportion of
women with persistent infection at endline. By contrast, because of the lower prevalence of
CIN2+ in Burkina Faso at baseline, fewer women were excluded in the follow-up analysis,
which potentially allowed a greater number of persistent HR-HPV cases to accrue during the
follow-up period. In addition, we cannot exclude the possibility that the 4-quadrant biopsy
may have helped clear HR-HPV from the cervical epithelium, as a greater proportion of
women in South Africa underwent a 4-quadrant biopsy.
HPV52 was the type most frequently detected overall in both countries, but HPV58 was the
type most strongly associated with cervical lesions, and one of the most likely to persist in both
countries. In a meta-analysis describing HPV type distribution among 5578 WLHIV from 20
studies including 5 from African countries, HPV16, 18 and 58 were the most prevalent among
those with cytological high-grade squamous intraepithelial lesions (HSIL+) [3, 26]. Addition-
ally, WLHIV with HSIL+ were less likely to harbour HPV16 compared to those with HSIL in
the general population, and more likely to be infected with HPV18/33/51/52/58, suggesting
HPV types and CIN2+ in HIV-1 infection
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that the HPV16/18 based bi/quadrivalent vaccines may have a lower impact on cervical cancer
rates in settings where HIV prevalence is high [27]. The high prevalence of types other than
HPV16 and HPV18 among WLHIV in this study is similar to what has been reported else-
where [6]. While we found that up to 45% of CIN2+ in BF and 37% of CIN2+ in SA could be
prevented by the HPV16/18-targeting vaccines, up to 90% of CIN2+ in BF and 80% of CIN2+
in SA could be prevented by the nonavalent vaccine, as predicted from studies in the general
population [8, 28].
We found that up to 45% of CIN2/3 in BF and 37% of CIN2/3 in SA could be prevented by
the HPV16/18-targeting vaccines, and that a further 45% of CIN2/3 in BF and 43% of CIN2/3
in SA could be prevented by the additional 5 types (HPV31/33/45/51/52) contained in the
nonavalent vaccine. However, not all CIN2/3 develop into invasive cervical cancer (ICC), and
not all HPV types found in CIN2 have the same propensity to evolve towards ICC. Clifford
et al, in their systematic review comparing the HPV type distribution in ICC biopsy and cervi-
cal specimens of 770 HIV-positive women from 21 studies in 12 African countries [29], report
a higher pooled prevalence of HPV16/18 (61.7%) than found in this study, whilst the preva-
lence of the other nonavalent vaccine types was 11.2%, lower than what we report in our study.
These findings indicate that the relative contribution of HPV16/18 increases with increasing
lesion grade, whilst the contribution of the additional nonavalent vaccine still represents a sig-
nificant preventable fraction of ICC.
Our study also shows that the persistence of any of the bi/quadrivalent and nonavalent
HR-HPV types is strongly associated with the incidence of cervical lesions among WLHIV, as
is the case for HIV uninfected women [30]. Moreover, our study found a significant propor-
tion of women had an incident infection with any of the nonavalent vaccine types (35%) as
well as incident infection of multiple HR-HPV types over the 16-month follow-up period. This
emphasises the potential impact of vaccination in this population using an HPV vaccine with a
broader-range protection potential, given that these types are also likely to persist in this popu-
lation [31].
A smaller but non-negligible proportion (11%) of women with CIN2+ were exclusively
infected by non-vaccine types at enrolment. In addition, the persistence of non-vaccine types
in the absence of current vaccine types, was also strongly associated with incident CIN2+, and
this was largely driven by persistence of HPV35 and 56. A large retrospective cross-sectional
study using histologically conformed ICC collected from 38 countries worldwide reported that
91% of cases were positive for any of the current nonavalent vaccine types in addition to
HPV35 [7]. Until further generation vaccines incorporate a wider range of HPV types, cervical
screening will remain important among WLHIV where non-vaccine types are prevalent.
ART-naïve women were at increased risk of HPV16 or 18 infection in South Africa at base-
line. Among ART users, a decrease in CD4+ count was also associated with an increased risk
of any of the nonavalent other than HPV16/18 and the non-vaccine type prevalence in Burkina
Faso, and of the non-vaccine types in South Africa. However, there was no reduction in
HPV16 or 18 prevalence with increasing CD4+ counts in either country. This is consistent
with previous reports suggesting that HPV16 might be more weakly associated with immune
suppression than other HR types due to its potential to evade the host immune response, thus
explaining its greater contribution to high-grade lesions and cancer in immunocompetent
women [32]. However, these associations may also be reflective of the overall increased risk of
any HR-HPV prevalence among those with low CD4+, as we have previously reported else-
where [14].
Given that the bi/quadrivalent and nonavalent types are the most important contributors to
cervical lesions in this population, maintaining a stable high CD4+ count is necessary to
reduce the risks of HR-HPV persistence and cervical lesion development. This should be
HPV types and CIN2+ in HIV-1 infection
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achieved by early initiation of ART before CD4+ counts decline and maintaining good HIV-1
virological control thereafter. In addition, HPV vaccination could be offered to these women
before CD4+ counts decline.
Limitations of this study include the absence of HPV genotyping from the biopsies, which
preclude accurate attribution of CIN to particular genotypes. Furthermore, our definition of
cumulative HR-HPV incidence over 16 months is at the same time crude and of limited dura-
tion to assess the actual roles of HR-HPV incidence and persistence on CIN2+ incidence.
Other studies have used shorter time intervals for defining HR-HPV incidence [33] because of
the transient nature of HR-HPV infection. Furthermore, the study could not rule out type-spe-
cific clearance and reinfection when estimating persistence during the 16-months interval
between HPV testing. The evaluation of HPV at two time points only did not allow precise
estimation of the duration of infections. Longer duration of follow-up would have allowed to
accrue a larger number of incident CIN2+ cases and more robustly assess the role of incident
HR-HPV on CIN development over sufficient follow-up time. A key strength of this study,
however, is the availability of a large proportion of women with verified histological endpoints
and concurrent genotyping data. In addition, the HARP study was undertaken in two African
countries with very different HIV epidemics and possibly different burdens of HPV infection
and cervical cancer, but the similarity of data allows the findings to be extended to a range of
countries and settings in sub-Saharan Africa.
In conclusion, we confirm that HR-HPV infection and cervical lesions are very common
among WLHIV in Africa, and that a broader range of genotypes are potentially associated
with CIN2+ development. While currently available bi/quadrivalent vaccines could prevent up
to 45% of treatable precursor lesions, the nonavalent vaccine has the potential to prevent up to
90% of cases in WLHIV. HPV vaccination could reduce the incidence of HR-HPV related dis-
ease among WLHIV in addition to contributing cost saving to current screening and treat-
ment programmes, but this would require a formal health economic evaluation.
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